PaxVax cholerae vaccine meets in Phase III

PaxVax Inc. (Redwood City, Calif.) said a single oral dose of PXVX0200 in a Phase III trial met the co-primary endpoint of reducing the incidence of moderate to severe diarrhea in subjects with Vibrio cholerae at 90 days post-vaccination vs. placebo (12.1% vs. 59%). In January, PaxVax reported data from 68 healthy volunteers in the trial showing that PXVX0200 met the other co-primary endpoint of reducing the incidence of moderate to severe diarrhea at 10 days post-vaccination vs. placebo (5.7% vs. 59%). ...